biostudies-literatureUnknown22(9)Lorenzoni VEdwards LifesciencesScuola Superiore Sant&apos;Anna<h4>Objectives</h4>To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk.<h4>Methods</h4>A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I-IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) weThe European journal of health economics : HEPAC : health economics in prevention and care1349-1363https://www.ebi.ac.uk/biostudies/studies/S-EPMC8558181biostudies-literatureThe cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups.PMC8558181Turchetti GSaia FBerti SCandolfi PLorenzoni VMeucci FMartinelli GLCerillo AGBarbieri GfalseThe cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups.<h4>Objectives</h4>To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk.<h4>Methods</h4>A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I-IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) we2021-01-01T00:00:00Z2021 Dec2025-04-26T02:51:36.333Z2022-02-11T12:46:59.989ZS-EPMC85581813401922010.1007/s10198-021-01314-z